DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for benign monoclonal gammopathy — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBenign monoclonal gammopathy maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for benign monoclonal gammopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
erb-b2 receptor tyrosine kinase 4 (ERBB4) — ERBB4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet iiidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2AHX · 2.396 Å · ligand YTTRIUM (III) ION (YT3). Experimental structure, not a prediction.
What the evidence adds up to
In a series of 88 cases of monoclonal gammopathy detected by general practitioners in Northern Jutland over three years, 80% were found to be benign disorders, 15% were malignant monoclonal gammopathy, and 5% were associated with non-haematologic cancers. The authors concluded that while the finding deserves attention, it is rarely accompanied by a grave prognosis and that a search for another type of cancer is not indicated. A triclonal gammopathy, involving three discrete monoclonal immunoglobulin subpopulations, is much rarer than monoclonal or biclonal gammopathies; a 1986 case report illustrates the diagnostic difficulties this condition presents to clinicians and laboratories. A 1989 paper in Clinical Chemistry describes a strategy for diagnosing monoclonal gammopathies in serum.
No drug, treatment, or intervention is mentioned in any of these abstracts. The evidence is limited to epidemiological description of the natural history of benign monoclonal gammopathy in a general practice setting, a single case report of a triclonal variant, and a diagnostic strategy paper. There are no data on any therapy, no survival curves, no response rates, and no randomised comparisons.
What is still missing is any clinical trial testing a drug for benign monoclonal gammopathy, any evidence that altering the condition changes outcomes, and any patient stratification beyond the broad benign-versus-malignant distinction reported in 1985. Money for such trials, a plausible drug candidate, and a trial design that could ethically randomise asymptomatic patients are all absent from this literature.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Chemistry · 1986 · 13 citations
Triclonal gammopathy in a patient with plasma cell dyscrasia.
AbstractA triclonal gammopathy is an immunoglobulin abnormality in which three discrete monoclonal subpopulations of immunoglobulin molecules are present in a patient's serum. Monoclonal and biclonal gammopathies have been studied extensively, but relatively little is known about the much rarer triclonal gammopathies. The case described below illustrates some of the difficulties that this condition can present to the clinician and the clinical laboratory.
Scandinavian Journal of Primary Health Care · 1985 · 2 citations · open access
Monoclonal Gammopathy in General Practice Associated Clinical Conditions
AbstractThe clinical diagnoses in all 88 cases of monoclonal gammopathy, detected by general practitioners in Northern Jutland during a 3-year period, were investigated: 15% had malignant monoclonal gammopathy, 5% had non-haematologic cancers, and in 80% a benign disorder was found. These results indicate that the finding of a monoclonal gammopathy in general practice deserves attention, but it is rarely accompanied by a grave prognosis. Malignant monoclonal gammopathy should be suspected, but search for another type of cancer is not indicated.
Clinical Chemistry · 1989 · 2 citations · open access
Strategy for diagnosis of monoclonal gammopathies in serum.
AbstractJournal Article Strategy for diagnosis of monoclonal gammopathies in serum. Get access S N Kahn S N Kahn Search for other works by this author on: Oxford Academic Google Scholar Clinical Chemistry, Volume 35, Issue 3, 1 March 1989, Pages 508–509, https://doi.org/10.1093/clinchem/35.3.508 Published: 01 March 1989
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
